GSK Rotarix Data Show Efficacy Against Virus Types Representing 98 Percent Of Rotavirus Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Data formed the basis of GSK’s BLA application for the rotavirus vaccine in the U.S., the company tells “The Pink Sheet” DAILY.